What are the common side effects of trametinib targeted drugs?

Trametinib is a selective MEK1/2 inhibitor, mainly used to treat melanoma carrying BRAF V600E or V600K mutations and a variety of other solid tumors. As an important drug targeting theRAS/RAF/MEK/ERK signaling pathway, its clinical application scope continues to expand, but side effect management has also become an important part of successful treatment. According to current research and real-world use experience, the side effects of trametinib are more targeted than traditional chemotherapy, but this does not mean that it is completely non-toxic. Its adverse reactions have certain regularity and predictability.

One of the most common side effects is skin toxicity, including rash, dry skin, itching, scaling, etc. Some patients develop erythematous papules on the face and trunk, sometimes accompanied by pigmentation or keratinization. Although most skin reactions are grade 1 to 2, if not treated in time, they may lead to dose adjustment or temporary discontinuation. The second type of common side effects is gastrointestinal reactions, such as nausea, vomiting, diarrhea and loss of appetite. Some patients will experience mild to moderate gastrointestinal discomfort in the early stages of treatment, which is related to the effect of the drug on the epithelial cell renewal cycle.

In addition, trametinib may also cause cardiac-related toxicities, including decreased ejection fraction (LVEF decreased) and QT interval prolongation. Although the incidence of these adverse events is not high, they are potentially serious and require regular electrocardiogram and echocardiographic monitoring. Another type of adverse reaction that deserves attention is abnormal vision. Patients may suffer from blurred vision, retinal detachment and other problems, which are closely related to the expression of the MEK pathway in retinal tissue.

Trametinib may also cause pulmonary adverse reactions, such as interstitial lung disease or non-infectious pneumonia and other rare but serious toxicities, usually manifested as dry cough, shortness of breath and chest tightness. Once discovered, the drug should be discontinued immediately for evaluation. In addition, when used in combination with dabrafenib, the incidence of systemic reactions such as fever and chills may be increased.

Reference materials:https://go.drugbank.com/drugs/DB08911